Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dermtech Inc
(NQ:
DMTK
)
2.400
-0.040 (-1.64%)
Streaming Delayed Price
Updated: 11:18 AM EDT, May 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dermtech Inc
< Previous
1
2
3
Next >
DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)
Today 8:00 EDT
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT)
May 11, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Appoints Bret Christensen as New President and CEO
May 09, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Reports First-Quarter 2023 Financial Results
May 04, 2023
From
DermTech, Inc.
Via
Business Wire
New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months
May 01, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
April 26, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech, Inc. (NASDAQ:DMTK) Investor Notice: Investigation over Possible Violations of Securities Laws
April 19, 2023
San Diego, CA -- (SBWIRE) -- 04/19/2023 -- DermTech, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
DermTech Announces Release Date for First-quarter 2023 Financial Results
April 13, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Contract With North Carolina Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
April 11, 2023
From
DermTech, Inc.
Via
Business Wire
New Survey Finds Millennials and Gen Xers Not Following Safe Sun Habits, Increasing Risk of Nonmelanoma Skin Cancer
April 05, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting
March 14, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
March 07, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech to Present at March Investor Conferences
March 03, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan
March 02, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
February 10, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
February 09, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 27, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
January 23, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
January 10, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
January 05, 2023
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2022
From
DermTech, Inc.
Via
Business Wire
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test
November 15, 2022
From
DermTech, Inc.
Via
Business Wire
DermTech Reports Third-Quarter 2022 Financial Results
November 03, 2022
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Release Date for Third-Quarter 2022 Financial Results
October 13, 2022
From
DermTech, Inc.
Via
Business Wire
DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress
October 10, 2022
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022
From
DermTech, Inc.
Via
Business Wire
DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California
October 03, 2022
From
DermTech, Inc.
Via
Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2022
From
DermTech, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.